Educational Grants
Alnylam Pharmaceuticals’ Educational Grants fund independent educational projects advancing clinical knowledge in ATTR amyloidosis, AHP, and PH1.
Browse similar grants
Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (monthly review; submit ≥45 days before activity start)
Funding Amounts: No set minimum or maximum; typical awards vary by project; up to $150,000 for some RFPs
Summary: Supports independent educational activities (CME, non-CME, and RFP responses) advancing clinical knowledge and patient care in ATTR amyloidosis, AHP, and PH1.
Key Information: Only organizations (not individuals) are eligible; requests must be in English and submitted via portal.
Description
Alnylam Pharmaceuticals offers educational grants to support independent, high-quality initiatives that advance clinical knowledge and improve patient care in the fields of transthyretin-mediated amyloidosis (ATTR amyloidosis), acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). Grants may support a wide range of activities, including continuing medical education (CME), non-CME programs, and responses to specific Requests for Proposals (RFPs). Supported projects should enhance disease awareness, promote evidence-based diagnostic and management practices, and encourage multidisciplinary collaboration, all while maintaining independence from Alnylam in both content and execution.
